Gordon AN - Search Results

1

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.

Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF. Gordon AN, et al. Gynecol Oncol. 2004 Aug;94(2):340-51. doi: 10.1016/j.ygyno.2004.04.024. Gynecol Oncol. 2004. PMID: 15297171 Clinical Trial.

2

Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.

Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M. Gordon AN, et al. Gynecol Oncol. 2002 Apr;85(1):129-35. doi: 10.1006/gyno.2001.6581. Gynecol Oncol. 2002. PMID: 11925132 Clinical Trial.

3

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.

McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P. McMeekin DS, et al. Gynecol Oncol. 2003 Jul;90(1):64-9. doi: 10.1016/s0090-8258(03)00203-8. Gynecol Oncol. 2003. PMID: 12821343 Clinical Trial.

4

Chemotherapeutic management of advanced ovarian cancer.

Gordon AN, Butler J. Gordon AN, et al. Semin Oncol Nurs. 2003 Aug;19(3 Suppl 1):3-18. doi: 10.1016/s0749-2081(03)00058-5. Semin Oncol Nurs. 2003. PMID: 12971247 Review.

5

Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH Jr, Bailey CL, Savage J, Young JA. Gordon AN, et al. Gynecol Oncol. 2004 Aug;94(2):533-9. doi: 10.1016/j.ygyno.2004.05.021. Gynecol Oncol. 2004. PMID: 15297200 Clinical Trial.

6

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Berek JS, et al. J Clin Oncol. 2004 Sep 1;22(17):3507-16. doi: 10.1200/JCO.2004.09.016. J Clin Oncol. 2004. PMID: 15337799 Clinical Trial.

7

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Gordon AN, et al. Gynecol Oncol. 2004 Oct;95(1):1-8. doi: 10.1016/j.ygyno.2004.07.011. Gynecol Oncol. 2004. PMID: 15385103 Clinical Trial.

8

Role of pegylated liposomal doxorubicin in ovarian cancer.

Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Thigpen JT, et al. Among authors: gordon an. Gynecol Oncol. 2005 Jan;96(1):10-8. doi: 10.1016/j.ygyno.2004.09.046. Gynecol Oncol. 2005. PMID: 15589573 Review.

9

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.

Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Gordon AN, et al. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92. doi: 10.1111/j.1525-1438.2005.00137.x. Int J Gynecol Cancer. 2005. PMID: 16174225 Free article. Clinical Trial.

10

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP 3rd. Seiden MV, et al. Among authors: gordon an. Gynecol Oncol. 2006 Apr;101(1):55-61. doi: 10.1016/j.ygyno.2005.09.036. Epub 2005 Nov 2. Gynecol Oncol. 2006. PMID: 16260029 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page